JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Phase 1

Completed

Conditions: Renal Insufficiency
Healthy

Interventions: Drug: Rivaroxaban (normal renal function)
Drug: Rivaroxaban (mild and moderate renal impairment)
Drug: Erythromycin (mild and moderate renal function)
Drug: Erythromycin (normal renal function)

First Posted Date: 2011-03-07

Last Posted Date: 2014-10-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 29

Registration Number: NCT01309438

A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease

Early Phase 1

Completed

Conditions: Asthma
Pulmonary Disease, Chronic Obstructive

Interventions: Other: Medical tests

First Posted Date: 2011-01-11

Last Posted Date: 2016-12-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 328

Registration Number: NCT01274507

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasm Metastases

Interventions: Drug: Sequence 1
Drug: Sequence 2

First Posted Date: 2011-01-10

Last Posted Date: 2014-11-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT01273480

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Phase 1

Completed

Conditions: Infarction
Stroke
Ischemia

Interventions: Drug: CNTO 0007 or placebo (Stage B)
Drug: CNTO 0007 or placebo (Stage A)

First Posted Date: 2011-01-10

Last Posted Date: 2014-03-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 13

Registration Number: NCT01273467

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Phase 1

Completed

Conditions: Neoplasm Metastases
Hepatic Insufficiency

Interventions: Drug: Trabectedin
Drug: Dexamethasone

First Posted Date: 2011-01-10

Last Posted Date: 2016-02-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 15

Registration Number: NCT01273493

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Placebo
Drug: CNTO 136

First Posted Date: 2011-01-10

Last Posted Date: 2016-03-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 25

Registration Number: NCT01273389

PRILIGY Usage Patterns in Selected Populations

Completed

Conditions: Sexual Dysfunction, Physiological

Interventions: Drug: PRILIGY (dapoxetine hydrochloride)

First Posted Date: 2011-01-10

Last Posted Date: 2014-04-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 3000

Registration Number: NCT01273545

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

Phase 2

Completed

Conditions: Patients Undergoing Repeat Peripheral Artery Revascularization

Interventions: Drug: CV-18C3
Procedure: Standard of Care

First Posted Date: 2011-01-05

Last Posted Date: 2021-02-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 43

Registration Number: NCT01270945

Locations: 🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
Sutter Heart & Vascular Institute, Sacramento, California, United States
🇺🇸
Mediquest Research Group, Ocala, Florida, United States

and more 5 locations

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasm Metastases

Interventions: Drug: Trabectedin
Drug: Ketoconazole
Drug: Dexamethasone or equivalent steroid

First Posted Date: 2010-12-24

Last Posted Date: 2015-10-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT01267084

Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: CA-18C3

First Posted Date: 2010-12-15

Last Posted Date: 2021-02-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT01260545

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy